-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145

Benzinga·10/15/2026 16:01:08
Listen to the news
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $146 to $145.